AlzeCure Pharma AB (publ) (STO:ALZCUR)
Sweden · Delayed Price · Currency is SEK 1.470
+0.090 (6.52%)
Apr 30, 2026, 12:06 PM CET
AlzeCure Pharma AB Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
168.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xbrane Biopharma AB | 152.35M |
| IRLAB Therapeutics AB | 57.46M |
| Elicera Therapeutics AB | 10.64M |
| NextCell Pharma AB | 9.83M |
| Xintela AB | 2.28M |
| Alligator Bioscience AB | 839.00K |
| Diamyd Medical AB | 362.00K |
AlzeCure Pharma AB News
- 8 months ago - AlzeCure Pharma AB Transcript: Status Update - Transcripts
- 1 year ago - AlzeCure Pharma AB Transcript: Study Update - Transcripts
- 2 years ago - AlzeCure Pharma AB Transcript: Status Update - Transcripts